Exagen Inc. (XGN) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. META
6. TSLA
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to Exagen Inc. (XGN) Misses Q4 EPS by 6c, Revenue Beats, Offers Guidance

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

March 20, 2023 4:05 PM EDT

SAN DIEGO, March 20, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year ended December 31, 2022.

Recent Highlights:

Record 135,210 flagship AVISE® CTD tests, for the full year 2022, including 33,819 tests for the fourth quarter of 2022. Since the launch of AVISE® CTD in 2012, we have now delivered approximately 750,000 of these tests.Total revenue of $45.6 million for the year ended December 31, 2022, and total revenue... More